Literature DB >> 8898378

A novel protease homolog differentially expressed in breast and ovarian cancer.

A Anisowicz1, G Sotiropoulou, G Stenman, S C Mok, R Sager.   

Abstract

BACKGROUND: Using differential display (DD), we discovered a new member of the serine protease family of protein-cleaving enzymes, named protease M. The gene is most closely related by sequence to the kallikreins, to prostate-specific antigen (PSA), and to trypsin. The diagnostic use of PSA in prostate cancer suggested that a related molecule might be a predictor for breast or ovarian cancer. This, in turn, led to studies designed to characterize the protein and to screen for its expression in cancer.
MATERIALS AND METHODS: The isolation of protease M by DD, the cloning and sequencing of the cDNA, and the comparison of the predicted protein structure with related proteins are described, as are methods to produce recombinant proteins and polyclonal antibody preparations. Protease M expression was examined in mammary, prostate, and ovarian cancer, as well as normal, cells and tissues. Stable transfectants expressing the protease M gene were produced in mammary carcinoma cells.
RESULTS: Protease M was localized by fluorescent in situ hybridization analysis to chromosome 19q13.3, in a region to which other kallikreins and PSA also map. The gene is expressed in the primary mammary carcinoma lines tested but not in the corresponding cell lines of metastatic origin. It is strongly expressed in ovarian cancer tissues and cell lines. The enzyme activity could not be established, because of difficulties in producing sufficient recombinant protein, a common problem with proteases. Transfectants were selected that overexpress the mRNA, but the protein levels remained very low.
CONCLUSIONS: Protease M expression (mRNA) may be a useful marker in the detection of primary mammary carcinomas, as well as primary ovarian cancers. Other medical applications are also likely, based on sequence relatedness to trypsin and PSA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8898378      PMCID: PMC2230195     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  35 in total

Review 1.  Kallikreins (kininogenases)--a group of serine proteases with bioregulatory actions.

Authors:  M Schachter
Journal:  Pharmacol Rev       Date:  1979-03       Impact factor: 25.468

2.  Kallikrein-related mRNAs of the rat submaxillary gland: nucleotide sequences of four distinct types including tonin.

Authors:  P L Ashley; R J MacDonald
Journal:  Biochemistry       Date:  1985-08-13       Impact factor: 3.162

3.  Cloning, characterization and nucleotide sequences of two cDNAs encoding human pancreatic trypsinogens.

Authors:  M Emi; Y Nakamura; M Ogawa; T Yamamoto; T Nishide; T Mori; K Matsubara
Journal:  Gene       Date:  1986       Impact factor: 3.688

4.  Human prostate-specific antigen: structural and functional similarity with serine proteases.

Authors:  K W Watt; P J Lee; T M'Timkulu; W P Chan; R Loor
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

5.  A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein.

Authors:  H Lilja
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

6.  Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs).

Authors:  S W Tsao; S C Mok; E G Fey; J A Fletcher; T S Wan; E C Chew; M G Muto; R C Knapp; R S Berkowitz
Journal:  Exp Cell Res       Date:  1995-06       Impact factor: 3.905

7.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

8.  Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs.

Authors:  M Kozak
Journal:  Nucleic Acids Res       Date:  1984-01-25       Impact factor: 16.971

9.  Nucleotide sequence of cloned cDNA for human pancreatic kallikrein.

Authors:  D Fukushima; N Kitamura; S Nakanishi
Journal:  Biochemistry       Date:  1985-12-31       Impact factor: 3.162

10.  Human kidney kallikrein: cDNA cloning and sequence analysis.

Authors:  A R Baker; J Shine
Journal:  DNA       Date:  1985-12
View more
  37 in total

Review 1.  Molecular genetics of ovarian cancer.

Authors:  A N Shelling; W Foulkes
Journal:  Mol Biotechnol       Date:  2001-09       Impact factor: 2.695

2.  Substrate specificity of human kallikreins 1 and 6 determined by phage display.

Authors:  Hai-Xin Li; Bum-Yeol Hwang; Gurunathan Laxmikanthan; Sachiko I Blaber; Michael Blaber; Pavel A Golubkov; Pengyu Ren; Brent L Iverson; George Georgiou
Journal:  Protein Sci       Date:  2008-04       Impact factor: 6.725

3.  Upregulation and secretion of kallikrein-related peptidase 6 (KLK6) in gastric cancer.

Authors:  Jin Ju Kim; Jong-Tae Kim; Hyo Ran Yoon; Min Ah Kang; Joo Heon Kim; Young-Ha Lee; Jae Wha Kim; Seon-Jin Lee; Eun Young Song; Pyung Keun Myung; Hee Gu Lee
Journal:  Tumour Biol       Date:  2012-02-29

4.  Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors.

Authors:  Maroulio Talieri; Marita Zoma; Marina Devetzi; Andreas Scorilas; Alexandros Ardavanis
Journal:  Tumour Biol       Date:  2012-04-03

5.  Re-expression of SPR1 in breast cancer cells by phorbol 12-myristate 13-acetate (PMA) or UV irradiation is mediated by the AP-1 binding site in the SPR1 promoter.

Authors:  A Anisowicz; G Sotiropoulou; R Sager
Journal:  Mol Med       Date:  1999-08       Impact factor: 6.354

6.  Expression of Kallikrein-Related Peptidase 6 in Primary Mucosal Malignant Melanoma of the Head and Neck.

Authors:  Julia Thierauf; Johannes A Veit; Jochen K Lennerz; Stephanie E Weissinger; Annette Affolter; Johannes Döscher; Christoph Bergmann; Andreas Knopf; Jennifer Grünow; Lisa Grünmüller; Cornelia Mauch; Peter K Plinkert; Thomas K Hoffmann; Jochen Hess
Journal:  Head Neck Pathol       Date:  2016-11-14

7.  Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer.

Authors:  Jane Bayani; Miltiadis Paliouras; Chris Planque; Shannon J C Shan; Cassandra Graham; Jeremy A Squire; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2008-07-22       Impact factor: 6.603

8.  Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration.

Authors:  Isobel A Scarisbrick; Rachel Linbo; Alexander G Vandell; Mark Keegan; Sachiko I Blaber; Michael Blaber; Diane Sneve; Claudia F Lucchinetti; Moses Rodriguez; Eleftherios P Diamandis
Journal:  Biol Chem       Date:  2008-06       Impact factor: 3.915

9.  KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes.

Authors:  Konstantinos G Sidiropoulos; Qiang Ding; Georgios Pampalakis; Nicole M A White; Peter Boulos; Georgia Sotiropoulou; George M Yousef
Journal:  Mol Oncol       Date:  2016-04-08       Impact factor: 6.603

10.  KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma.

Authors:  N M A White; M Mathews; G M Yousef; A Prizada; C Popadiuk; J J E Doré
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.